Erasca, Inc.

Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product candidate is naporafenib, which is currently in pivotal Phase 3 trials (SEACRAFT-2) for patients with NRAS-mutated melanoma. Erasca's pipeline also includes ERAS-0015, a pan-RAS molecular glue designed to treat RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for KRAS-altered solid tumors; and ERAS-12, an investigational EGFR biparatopic antibody for solid tumors. The company employs a modality-agnostic approach to targeting the RAS/MAPK signaling pathway, which is implicated in many human cancers. Erasca maintains a robust cash position to support its clinical development programs and has secured composition of matter patent protection for its key molecules extending through 2043. As a precision oncology specialist, Erasca addresses treatment opportunities in patient populations defined by specific genetic mutations in cancer-driving pathways.